InMatrico®
Tissue-specific extracellular matrix kits and assays for predictive disease modeling and drug testing
Technology
Tissue-specific decellularized ECMs
Predictive results consistent with those in patients: TissueSpec® dECMs enable physiologically-relevant disease modeling and drug testing in matrico by providing the tissue-specific biochemical and mechanical ECM signals lacking in vitro.
Primary tissues
Tissues are comprised of cells attached to ECM.
Tissue-specific dECMs
Tissue decellularization (cell removal) yields tissue-specific decellularized ECM (dECM).
TissueSpec® dECM Kits
Decellularized ECM (dECM) is processed into dECM coating and hydrogel kits.
Primary tissues are decellularized using proprietary protocols to obtain tissue-specific decellularized ECMs (dECM), which are then processed into quality-controlled, ready-to-use TissueSpec® dECM Coating and Hydrogel Kits.
International Distributors
Explore the map to find distributors near you.
News
Read more
JUN. 14, 2024
Xylyx Bio Awarded $2.26M NIH SBIR Grant from National Cancer Institute
Read more
April 5, 2022
Xylyx Bio collaboration reveals new insights into tumor drug resistance
Read more
Sept. 2, 2021